CD274 and hepatocellular carcinoma: Data from IMbrave150, a phase III first-line trial in unresectable HCC, showed that after a median follow-up of 15.6 months, atezolizumab (anti-PD-L1) in combination with bevacizumab (anti-angiogenetic VEGF drug) reduced the risk of OS by 34%, with a median OS of 19.2 months, compared to 13.4 months for the TKI sorafenib.